Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.

PloS One
Sharad P AdekarScott K Dessain

Abstract

Botulinum neurotoxins (BoNT) are a family of category A select bioterror agents and the most potent biological toxins known. Cloned antibody therapeutics hold considerable promise as BoNT therapeutics, but the therapeutic utility of antibodies that bind the BoNT light chain domain (LC), a metalloprotease that functions in the cytosol of cholinergic neurons, has not been thoroughly explored. We used an optimized hybridoma method to clone a fully human antibody specific for the LC of serotype A BoNT (BoNT/A). The 4LCA antibody demonstrated potent in vivo neutralization when administered alone and collaborated with an antibody specific for the HC. In Neuro-2a neuroblastoma cells, the 4LCA antibody prevented the cleavage of the BoNT/A proteolytic target, SNAP-25. Unlike an antibody specific for the HC, the 4LCA antibody did not block entry of BoNT/A into cultured cells. Instead, it was taken up into synaptic vesicles along with BoNT/A. The 4LCA antibody also directly inhibited BoNT/A catalytic activity in vitro. An antibody specific for the BoNT/A LC can potently inhibit BoNT/A in vivo and in vitro, using mechanisms not previously associated with BoNT-neutralizing antibodies. Antibodies specific for BoNT LC may be valuable componen...Continue Reading

References

Apr 4, 2000·Physiological Reviews·G SchiavoC Montecucco
Oct 12, 2000·Nucleic Acids Research·J A CoronellaR P Junghans
Mar 7, 2001·JAMA : the Journal of the American Medical Association·S S ArnonUNKNOWN Working Group on Civilian Biodefense
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·A NowakowskiJ D Marks
Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Lance L Simpson
Mar 18, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·James D Marks
Apr 9, 2004·Journal of Clinical Microbiology·Jason R Barash, Stephen S Arnon
Aug 6, 2004·Protein Expression and Purification·Michael R BaldwinJoseph T Barbieri
Sep 4, 2004·Journal of Immunological Methods·Scott K DessainRobert A Weinberg
Dec 21, 2004·Nucleic Acids Research·Marie-Paule LefrancGérard Lefranc
Jan 28, 2005·Assay and Drug Development Technologies·Ryan J Darling, Pierre-Alexandre Brault
Jun 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Lawrence M Wein, Yifan Liu
Mar 18, 2006·Science·Min DongEdwin R Chapman
Jun 20, 2006·The Journal of Pharmacology and Experimental Therapeutics·Easwaran RavichandranLance L Simpson
Oct 4, 2006·EMBO Reports·Claudia VerderioMichela Matteoli
Feb 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Lisa M EubanksKim D Janda
Jun 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Audrey Fischer, Mauricio Montal
Feb 21, 2008·Infection and Immunity·Greice Krautz-PetersonAbhineet S Sheoran
Feb 26, 2008·Hybridoma·Sharad P AdekarScott K Dessain
May 1, 2008·PloS One·Karine BagramyanMarkus Kalkum
Jun 3, 2011·Cold Spring Harbor Protocols·Marie-Paule Lefranc

❮ Previous
Next ❯

Citations

Nov 18, 2009·Infection and Immunity·Jorge SepulvedaCharles B Shoemaker
May 26, 2009·Applied Biochemistry and Biotechnology·Wei-Gang HuLes P Nagata
Sep 9, 2011·Bioorganicheskaia khimiia·S G AbbasovaE V Grishin
May 11, 2013·Expert Review of Vaccines·Robert P Webb, Leonard A Smith
May 8, 2010·Trends in Biotechnology·Angel M CuestaLuis Alvarez-Vallina
Mar 17, 2009·Toxicon : Official Journal of the International Society on Toxinology·M Zouhair Atassi
Sep 19, 2015·MAbs·Christine Rasetti-EscargueilDorothea Sesardic
Nov 30, 2011·MAbs·Jeffrey W FroudePhilippe Thullier
Nov 13, 2012·Biotechnology Advances·Vipin Chandra Kalia
Mar 20, 2013·Proceedings of the National Academy of Sciences of the United States of America·Desirée A BenefieldD Borden Lacy
Mar 9, 2017·Expert Opinion on Drug Discovery·Marco Pirazzini, Ornella Rossetto
May 15, 2013·Infection and Immunity·Amanda PrzedpelskiJoseph T Barbieri
Sep 25, 2019·Toxins·Christine Rasetti-Escargueil, Michel R Popoff
Aug 26, 2016·PloS One·Sebastian MietheMichel Robert Popoff
Dec 17, 2011·Toxins·Jeffrey W FroudeThibaut Pelat
Jul 24, 2012·Toxins·Siu-Kei Chow, Arturo Casadevall
Jan 20, 2019·Toxins·Timothy Patrick JenkinsAndreas Hougaard Laustsen
Dec 8, 2010·Analytical Biochemistry·Géraldine FerracciChristian Lévêque
May 11, 2021·Infectious Diseases·Luca AntonucciRoberto Antonucci

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence resonance
fluorescence resonance energy transfer assay
confocal microscopy
gradient density centrifugation
fluorescent

Software Mentioned

Fluoview

Related Concepts

Related Feeds

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.